LM-2417 + carboplatin

LM-2417 + carboplatin is a combination therapy under investigation for advanced solid tumors. LM-2417 is described as an **anti-NaPi2b bispecific antibody, potentially also engaging the 4-1BB co-stimulatory domain** to enhance anti-tumor immune activity[4]. Carboplatin is a **platinum-based chemotherapeutic agent** that induces DNA damage leading to apoptosis in rapidly dividing cancer cells. The combination is being evaluated in **Phase I/II clinical trials in patients with advanced solid tumors** with the primary objective of assessing safety, tolerability, and early signals of efficacy as part of multi-arm, combination regimens[1][3][4]. This investigational regimen is developed by LaNova Medicines.